IN2012DN01254A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01254A IN2012DN01254A IN1254DEN2012A IN2012DN01254A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A IN 1254DEN2012 A IN1254DEN2012 A IN 1254DEN2012A IN 2012DN01254 A IN2012DN01254 A IN 2012DN01254A
- Authority
- IN
- India
- Prior art keywords
- compounds
- enteralor
- ainfections
- isozazole
- substituents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Abstract
Compounds which exhibit antiviral activity, particularly against influenza virus,and methods of making and using there of are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteralor parenteral administration. The compounds are preferably used to treat or prevent Influenza Ainfections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23143109P | 2009-08-05 | 2009-08-05 | |
PCT/CN2010/001187 WO2011015037A1 (en) | 2009-08-05 | 2010-08-05 | Antiviral compounds and methods of making and using there of cross reference to related applications |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01254A true IN2012DN01254A (en) | 2015-05-15 |
Family
ID=43543887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1254DEN2012 IN2012DN01254A (en) | 2009-08-05 | 2010-08-05 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2462138B1 (en) |
JP (1) | JP2013501008A (en) |
KR (1) | KR20120092567A (en) |
CN (1) | CN102596946B (en) |
AU (1) | AU2010281265A1 (en) |
BR (1) | BR112012002331A2 (en) |
CA (1) | CA2770140A1 (en) |
IL (1) | IL217745A0 (en) |
IN (1) | IN2012DN01254A (en) |
MX (1) | MX2012001504A (en) |
RU (1) | RU2012104214A (en) |
SG (1) | SG178106A1 (en) |
WO (1) | WO2011015037A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
WO2011147198A1 (en) * | 2010-05-28 | 2011-12-01 | Versitech Limited | Compounds and methods for treatment of proliferative diseases |
PL2614052T3 (en) * | 2010-09-08 | 2015-06-30 | Bristol Myers Squibb Co | Novel piperazine analogs as broad-spectrum influenza antivirals |
JP2013542201A (en) * | 2010-09-28 | 2013-11-21 | ブリストル−マイヤーズ スクイブ カンパニー | Novel piperazine analogues with substituted heteroaryl groups as broad spectrum influenza antiviral agents |
UY33337A (en) | 2010-10-18 | 2011-10-31 | Respivert Ltd | SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
US20140011700A1 (en) * | 2011-03-25 | 2014-01-09 | Bristol-Myers Squibb Company | Three-dimensional structure of h1n1 nucleoprotein in complex with antiviral compounds |
KR101369584B1 (en) * | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | Phenyl-isoxazol derivatives and preparation process thereof |
CN102432555A (en) * | 2011-09-09 | 2012-05-02 | 中国科学院广州生物医药与健康研究院 | 1, 2, 3-triazole-4 (5) carboxamide compound and application thereof |
LT2834244T (en) | 2012-03-13 | 2016-11-10 | Respivert Limited | Crystalline pi3 kinase inhibitors |
US9676734B2 (en) | 2012-05-18 | 2017-06-13 | Vironova Influenza Ab | Compounds and methods |
SG11201407703QA (en) * | 2012-05-18 | 2015-01-29 | Vironova Ab | Methanethione compounds having antiviral activity |
HUE042374T2 (en) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
JO3279B1 (en) | 2013-03-15 | 2018-09-16 | Respivert Ltd | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors |
EA035095B1 (en) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Bicyclic heterocycles as fgfr inhibitors |
JP6397912B2 (en) * | 2013-07-30 | 2018-09-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Substituted pyridine piperazinyl analogs as RSV antiviral compounds |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
CN113004278B (en) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | Bicyclic heterocycles as FGFR inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
CN107056762B (en) * | 2016-12-22 | 2020-08-28 | 四川百利药业有限责任公司 | Bis-carbonyl analogues for use against influenza virus |
US11040963B2 (en) | 2017-02-02 | 2021-06-22 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibitions |
WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
TWI793151B (en) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
AU2019262579A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Salts of an FGFR inhibitor |
AU2019262195A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
WO2020012334A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
MA54758A (en) | 2019-01-18 | 2022-04-27 | Astrazeneca Ab | PCSK9 INHIBITORS AND METHODS OF USE THEREOF |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
TWI765323B (en) * | 2019-08-22 | 2022-05-21 | 大陸商四川海思科製藥有限公司 | Anti-influenza virus compound and preparation method and use thereof |
BR112022007163A2 (en) | 2019-10-14 | 2022-08-23 | Incyte Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (en) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Tricyclic heterocycles as FGFR inhibitors |
KR20220131900A (en) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Derivatives of FGFR inhibitors |
TWI794742B (en) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | Antiviral compounds |
WO2021204924A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Compounds for use in the treatment of hypercytokinemia |
WO2021204923A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Antiviral agents |
WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05117150A (en) | 1991-10-25 | 1993-05-14 | Sanwa Kagaku Kenkyusho Co Ltd | Antiviral agent |
KR200293242Y1 (en) * | 2002-04-18 | 2002-11-01 | 전이범 | Oxygen cutting hose |
DE10236564A1 (en) * | 2002-08-08 | 2004-05-19 | Ursapharm Arzneimittel Gmbh & Co. Kg | Use of papaverine-like vasodilator and pharmaceutical composition |
BRPI0607688A2 (en) * | 2005-02-17 | 2009-09-22 | Synta Pharmaceuticals Corp | method for inhibiting tubulin polymerization in a cell; method for treating or preventing a proliferative disorder in an individual; method of blocking, occluding or otherwise disrupting blood flow to the neovasculature; compound; pharmaceutical composition and use of said method and compound |
JP2011507910A (en) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | Methods for changing the lifetime of eukaryotes |
-
2010
- 2010-08-05 BR BR112012002331A patent/BR112012002331A2/en not_active IP Right Cessation
- 2010-08-05 JP JP2012523184A patent/JP2013501008A/en active Pending
- 2010-08-05 MX MX2012001504A patent/MX2012001504A/en not_active Application Discontinuation
- 2010-08-05 SG SG2012005450A patent/SG178106A1/en unknown
- 2010-08-05 AU AU2010281265A patent/AU2010281265A1/en not_active Abandoned
- 2010-08-05 RU RU2012104214/04A patent/RU2012104214A/en not_active Application Discontinuation
- 2010-08-05 EP EP10805941.1A patent/EP2462138B1/en active Active
- 2010-08-05 CN CN201080044361.6A patent/CN102596946B/en active Active
- 2010-08-05 KR KR1020127005837A patent/KR20120092567A/en not_active Application Discontinuation
- 2010-08-05 IN IN1254DEN2012 patent/IN2012DN01254A/en unknown
- 2010-08-05 WO PCT/CN2010/001187 patent/WO2011015037A1/en active Application Filing
- 2010-08-05 CA CA2770140A patent/CA2770140A1/en not_active Abandoned
-
2012
- 2012-01-26 IL IL217745A patent/IL217745A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG178106A1 (en) | 2012-03-29 |
AU2010281265A2 (en) | 2012-04-05 |
EP2462138B1 (en) | 2014-09-24 |
BR112012002331A2 (en) | 2019-09-24 |
IL217745A0 (en) | 2012-03-29 |
EP2462138A4 (en) | 2013-01-23 |
WO2011015037A1 (en) | 2011-02-10 |
CA2770140A1 (en) | 2011-02-10 |
KR20120092567A (en) | 2012-08-21 |
JP2013501008A (en) | 2013-01-10 |
CN102596946A (en) | 2012-07-18 |
MX2012001504A (en) | 2012-06-01 |
CN102596946B (en) | 2015-06-17 |
RU2012104214A (en) | 2013-09-10 |
EP2462138A1 (en) | 2012-06-13 |
AU2010281265A1 (en) | 2012-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01254A (en) | ||
PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
PE20160127A1 (en) | ACID COMPOUND (2S, 3S) -3 - ((2- (5-FLUORO-1H-PIRROLO [2,3-B] PYRIDIN-3-IL) -5-FLUOROPYRIMIDIN-4-IL) AMINO) BICICLO [2.2. 2] OCTANE-2-CARBOXYL AS AN INHIBITOR OF THE REPLICATION OF THE FLU VIRUS TO H1N1, H2N2, H3N2 or H5N1 | |
EA201391127A1 (en) | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH INHIBITOR ACTIVITY OF HIV MATURATION | |
EA201270800A1 (en) | C-28 AMIDES OF MODIFIED DERIVATIVES OF C-3 BETULINIC ACID AS AN HIV INHIBITORS INHIBITORS | |
UA113956C2 (en) | PIRIMIDIN DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | |
UY34350A (en) | DERIVATIVES OF PIRAZOLQUINOLINONA, ITS PREPARATION AND THERAPEUTIC USE. | |
PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
MY165584A (en) | Ampk-activating heterocyclic compounds and methods for using the same | |
MX2022009352A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus. | |
MX2015010354A (en) | C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv. | |
BR112015013463A8 (en) | INDOL CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | |
EA201490643A1 (en) | NEW BETULINIC ACID DERIVATIVES WITH ANTI-VIRUS ACTIVITY | |
Boyd et al. | Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors | |
UY34314A (en) | DERIVATIVES OF ANILINA, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION. | |
PH12014501415A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
EA201190234A1 (en) | NEW AMIDA DERIVATIVES OF STEROID COMPOUNDS [3,2-C] PYRAZOLS WITH GLUCOCORTICOID ACTIVITY | |
EA201190236A1 (en) | NEW DERIVATIVES OF STEROID COMPOUNDS [3,2-C] PYRAZOLS WITH GLUCOCORTICOID ACTIVITY | |
SG194711A1 (en) | Processes for preparing inhibitors of the hepatitis c virus | |
ECSP13013080A (en) | USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA | |
IN2011CH03893A (en) | ||
EA201370058A1 (en) | MEANS AGAINST FLU VIRUS B | |
EA201370057A1 (en) | MEANS AGAINST FLU VIRUS B | |
MX2012014853A (en) | Rna synthetic molecules obtained from novel plasma vectors, methods for obtaining the same and use thereof as positive controls in the detection of influenza h1n1. | |
TN2013000456A1 (en) | Pyrazole derivatives useful as aldosterone synthase inhibitors |